Search results
Father, daughter riding for Roswell Park donor center
WGRZ-TV Buffalo· 20 hours agoThe father-daughter duo is nearing their goal of raising $25,000. The fundraising rivalry between...
Penny Stock Picks: 3 Companies Poised to Graduate to the Big Leagues
InvestorPlace· 5 days agoYou don’t want to overlook these three penny stocks filled to the brim with the potential to make...
Aptose Announces Results from Annual and Special Meeting of Shareholders
Digital Journal· 4 days ago...The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (TUS), an oral, kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and...
Oxford teacher donates bone marrow to help a man with leukemia in Italy
WBRC Fox 6 Birmingham· 3 days agoThis week, an east Alabama educator is helping a man living 5,000 miles away get a second chance at...
New Standard of Care in High-Risk Acute Promyelocytic Leukemia?
MedPage Today· 6 days agoCombining all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and idarubicin significantly...
xQc defends Kick after ex-staff’s “sinister” allegations against platform - Dexerto
Dexerto· 4 days agoJust a day after a former Kick employee uploaded a video detailing issues they had with the company,...
Hemogenyx Pharmaceuticals PLC Announces Operations Update
Digital Journal· 6 days agoOperations Update LONDON, UNITED KINGDOM / ACCESSWIRE / June 17, 2024 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the clinical stage biopharmaceutical group developing treatments for cancers and viral diseases, is pleased to provide an update on its
Educational Development Corporation Announces Executed Fifth Amendment to Credit Agreement
Digital Journal· 5 days ago...Partners with National Cyber Security to Provide Cyber Protection for Homeowners Biopharma Stocks Quest for Solutions for Acute Myeloid Leukemia (AML) CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment Atlas Lithium Doubles the Size...
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's...
Benzinga· 5 days agoShares of Ovid Therapeutics Inc OVID dipped 65.7% to $1.1285 after Takeda’s Skyline study in Dravet syndrome missed its primary endpoint. Takeda Pharmaceutical Co Ltd TAK announced topline data ...
Cullinan Therapeutics (NASDAQ:CGEM) Shares Gap Down to $18.88
ETF DAILY NEWS· 4 days agoCullinan Therapeutics, Inc. (NASDAQ:CGEM – Get Free Report) shares gapped down prior to trading on Monday . Cullinan Therapeutics shares last traded at $18.56, with a volume of 60,955 shares ...
